Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,548 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pushkal Garg also recently made the following trade(s):

• On Friday, February 14th, Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $255.17, for a total value of $398,320.37.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $250.00 on Wednesday. The firm has a market cap of $32.25 billion, a PE ratio of -95.42 and a beta of 0.35. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a 50 day moving average of $253.96 and a 200-day moving average of $263.29. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, February 14th. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Finally, Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $299.48.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Huntington National Bank lifted its stake in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $33,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.